Kane Biotech Statistics
Total Valuation
Kane Biotech has a market cap or net worth of 10.59 million. The enterprise value is 11.84 million.
| Market Cap | 10.59M |
| Enterprise Value | 11.84M |
Important Dates
The next estimated earnings date is Thursday, May 22, 2025.
| Earnings Date | May 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.72% |
| Shares Change (QoQ) | -15.33% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 100.70M |
Valuation Ratios
The trailing PE ratio is 2.55.
| PE Ratio | 2.55 |
| Forward PE | n/a |
| PS Ratio | 7.11 |
| PB Ratio | -20.77 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.86 |
| EV / Sales | 8.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.83 |
Financial Position
The company has a current ratio of 0.80
| Current Ratio | 0.80 |
| Quick Ratio | 0.48 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.41 |
| Interest Coverage | -5.48 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -52.36% |
| Return on Invested Capital (ROIC) | -137.03% |
| Return on Capital Employed (ROCE) | -362.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.41 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.72% in the last 52 weeks. The beta is 0.25, so Kane Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -25.72% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.09 |
| Relative Strength Index (RSI) | 42.87 |
| Average Volume (20 Days) | 13,965 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kane Biotech had revenue of 1.49 million and earned 4.14 million in profits. Earnings per share was 0.03.
| Revenue | 1.49M |
| Gross Profit | 735,484 |
| Operating Income | -3.07M |
| Pretax Income | -3.64M |
| Net Income | 4.14M |
| EBITDA | -3.08M |
| EBIT | -3.07M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 402,959 in cash and 1.70 million in debt, giving a net cash position of -1.29 million.
| Cash & Cash Equivalents | 402,959 |
| Total Debt | 1.70M |
| Net Cash | -1.29M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -509,749 |
| Book Value Per Share | -0.00 |
| Working Capital | -405,291 |
Cash Flow
In the last 12 months, operating cash flow was -4.16 million and capital expenditures -19,728, giving a free cash flow of -4.18 million.
| Operating Cash Flow | -4.16M |
| Capital Expenditures | -19,728 |
| Free Cash Flow | -4.18M |
| FCF Per Share | n/a |
Margins
Gross margin is 49.36%, with operating and profit margins of -206.36% and 278.16%.
| Gross Margin | 49.36% |
| Operating Margin | -206.36% |
| Pretax Margin | -243.98% |
| Profit Margin | 278.16% |
| EBITDA Margin | -206.42% |
| EBIT Margin | -206.36% |
| FCF Margin | n/a |
Dividends & Yields
Kane Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.72% |
| Shareholder Yield | -4.72% |
| Earnings Yield | 39.14% |
| FCF Yield | -39.48% |
Stock Splits
The last stock split was on March 13, 2017. It was a reverse split with a ratio of 0.2.
| Last Split Date | Mar 13, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Kane Biotech has an Altman Z-Score of -13.2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.2 |
| Piotroski F-Score | n/a |